基于多参数MRI定量特征无创识别HER2零表达、低表达与过表达乳腺癌
本回顾性研究纳入114例同时行DWI和SyMRI的乳腺癌患者,按病理HER2状态分为过表达组40例、低表达组53例和零表达组21例,评估SyMRI定量参数与ADC对HER2状态的鉴别效能。结果显示PDe鉴别HER2低表达与过表达的AUC为0.849,PDe与ADC联合鉴别HER2零表达与低表达的AUC提高至0.825。
要点
- PDe鉴别HER2低表达与过表达乳腺癌的AUC为0.849(95%CI 0.760-0.915)。
- PDe鉴别HER2零表达与低表达的AUC为0.765(95%CI 0.652-0.855)。
- PDe联合ADC后鉴别HER2零表达与低表达的AUC提高至0.825(95%CI 0.719-0.903)。
核心结论
- SyMRI可无创且稳健地预测乳腺癌患者的HER2表达状态。
研究设计与样本
- 回顾性研究,纳入114例同时行DWI和SyMRI的乳腺癌女性患者,按病理HER2状态分为过表达组40例、低表达组53例和零表达组21例,以病理为参考标准。
关键影像表现/征象
- SyMRI定量指标在三个HER2亚组乳腺癌间差异有统计学意义,ΔT2除外(p<0.05)。
- PR状态、Ki-67指数和腋窝淋巴结计数在HER2零表达、低表达和过表达组间差异有统计学意义(p<0.001至p=0.03)。
诊断标准与关键数值
- PDe鉴别HER2低表达与过表达乳腺癌的AUC为0.849(95%CI 0.760-0.915)。
- PDe鉴别HER2零表达与低表达的AUC为0.765(95%CI 0.652-0.855)。
- ADC鉴别HER2零表达与低表达的AUC为0.684(95%CI 0.565-0.787)。
- PDe联合ADC鉴别HER2零表达与低表达的AUC为0.825(95%CI 0.719-0.903)。
临床应用与阅片要点
- 作者认为SyMRI可无创且稳健地预测乳腺癌患者的HER2表达状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the effectiveness of both synthetic magnetic resonance imaging (SyMRI) and conventional diffusion-weighted imaging (DWI) for identifying the human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) patients.
METHOD: In this retrospective study, 114 women with DWI and SyMRI were pathologically classified into three groups: HER2-overexpressing (n = 40), HER2-low-expressing (n = 53), and HER2-zero-expressing (n = 21). T1 and T2 relaxation times and proton density (PD) were assessed before and after enhancement, and the resulting quantitative parameters produced by SyMRI were recorded as T1, T2, and PD and T1e, T2e, and PDe. Logistic regression was used to identify the best indicators for classifying patients based on HER2 expression. The discriminative performance of the models was evaluated using receiver operating characteristic (ROC) curves.
RESULTS: Our preliminary study revealed significant differences in progesterone receptor (PR) status, Ki-67 index, and axillary lymph node (ALN) count among the HER2-zero, -low, and -overexpressing groups (p < 0.001 to p = 0.03). SyMRI quantitative indices showed significant differences among BCs in the three HER2 subgroups, except for ΔT2 (p < 0.05). our results indicate that PDe achieved an area under the curve(AUC)of 0.849 (95 % CI: 0.760-0.915) for distinguishing HER2-low and -overexpressing BCs. Further investigation revealed that both the PDe and ADC were indicators for predicting differences among patients with HER2-zero and HER2-low-expressing BC, with AUCs of 0.765(95 % CI: 0.652-0.855) and 0.684(95 % CI: 0.565-0.787), respectively. The addition of the PDe to the ADC improved the AUC to 0.825(95 % CI: 0.719-0.903).
CONCLUSIONS: SyMRI could noninvasively and robustly predict the HER2 expression status of patients with BC.
引用
- Zhan T, Dai J, Li Y, et al. Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer. Eur J Radiol. 2024. PMID: 38905803. doi:10.1016/j.ejrad.2024.111573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。